Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy
Journal of Medicinal Chemistry · 14.11.2026
DOI: 10.1021/acs.jmedchem.6c02082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 14.11.2026. Verfasst von Danfeng Wang und 10 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Ministry of Education of the People's Republic of China, National Key Research and Development Program of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Blocking PD-1/PD-L1 interaction shows remarkable antitumor efficacy clinically but systemic administration can cause immune-related adverse events in multiple organs from nonspecific T-cell activation, restricting the clinical safety window. Achieving spatiotemporal regulation of immune checkpoint blockadepreserving antitumor immunity while avoiding systemic toxicityis a key challenge. Prodrug strategies, particularly photocaging, enable on-demand light-triggered drug activation. Here, we propose a prodrug design for small-molecule PD-L1 inhibitors using coumarin photocaging groups. Guided by cocrystal binding mode analysis, we covalently masked two inhibitors with coumarin photolabile protecting groups, and designed and synthesized the corresponding photocaged prodrugs. In vitro, the prodrugs were inactive under dark conditions, but upon visible light activation, they restored T-cell effector function and restored T-cell effector function in PD-L1-dependent co-culture models. These results validate the on-demand release pharmacological property, providing a feasible approach for spatiotemporally controllable immunotherapy in superficial or optically accessible lesions.
Förderung
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, D., Jiang, B., Yang, P., Wang, H., Wang, L., Xia, G., Zhu, L., Wang, L., Xiao, Y., Sun, C., & Yang, P. (2026). Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02082
Vancouver
Wang D, Jiang B, Yang P, Wang H, Wang L, Xia G, et al. Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02082
BibTeX
@article{Wang2026,
author = {Wang, Danfeng and Jiang, Binjian and Yang, Pan and Wang, Hongxia and Wang, Lili and Xia, Guangqi and Zhu, Lili and Wang, Liping and Xiao, Yibei and Sun, Chengliang and Yang, Peng},
title = {Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c02082}
}
EUVIMED